Inactive Instrument

Highlights Peloton Therapeutics, Inc.

Equities

Merck & Co., Inc. completed the acquisition of Peloton Therapeutics, Inc. from The Column Group LLC.	19-07-29	CI
Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.	19-07-10	CI
Merck & Co., Inc. signed a definitive agreement to acquire Peloton Therapeutics, Inc. from The Column Group LLC for $2.2 billion.	19-05-20	CI
Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.	19-04-26	CI
Peloton Therapeutics To Seek Acquisitions	19-04-26	CI
Peloton Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer	18-08-14	CI
Peloton Therapeutics Initiates Phase 2 Trial of OralHIF-2a Inhibitor PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Kidney Cancer	18-06-06	CI
Peloton Therapeutics, Inc. Announces Results from A Phase 1 Study Evaluating PT2385 in Patients with Advanced Kidney Cancer	17-12-20	CI
Peloton Therapeutics, Inc. Initiates Patient Dosing in Phase 2 Study of PT2385 for Von Hippel-Lindau Disease-Associated Kidney Cancer	17-05-11	CI
Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibitor in Patients with Advanced Kidney Cancer	16-06-06	CI
Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2a Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting	16-04-19	CI

No results for this search